Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad5-105K
- Development stage
- Phase 1
- Lead developer
- CanSino Biologics
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
Ad5-105K is a nebulized recombinant replication-deficient adenovirus serotype 5 (Ad5)-based vaccine being developed by CanSino Biologics. It utilizes an Ad5 vector platform to deliver genetic material encoding a target antigen, stimulating an immune response. The vaccine is designed for respiratory administration via nebulization and is currently in early-phase clinical trials to evaluate its safety and immunogenicity in healthy adults. The primary mechanism involves the delivery of antigenic genes using the Ad5 vector, which induces both innate and adaptive immune responses through activation of antigen-presenting cells and stimulation of cytotoxic T lymphocytes[1][2].
- Other names
- Ad5-105K Inhaled TB VaccineAd-5-105K Inhaled TB VaccineAd 5-105K Inhaled TB VaccineTuberculosis (TB) vaccine (Ad5-105K)
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on Ad5-105K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad5-105K.